JILIN AODONG(SZ:000623) Xin Lang Cai Jing·2025-11-21 06:48Core Viewpoint - Jilin Aodong's stock price has experienced a continuous decline, with a 5.09% drop on November 21, leading to a total market value of 22.72 billion yuan and a cumulative decline of 6.23% over five days [1] Group 1: Company Overview - Jilin Aodong Pharmaceutical Group Co., Ltd. was established on March 20, 1993, and listed on October 28, 1996 [1] - The company is primarily engaged in the research, development, manufacturing, and sales of traditional Chinese medicine, biochemical drugs, and is also expanding into health food, food, breeding, and planting sectors [1] - The revenue composition of the company includes: Traditional Chinese medicine 60.90%, chain pharmacy wholesale and retail 16.59%, chemical drugs 12.73%, food 7.39%, other products 1.76%, and others (supplementary) 0.62% [1] Group 2: Fund Holdings - One fund under China Merchants Fund holds a significant position in Jilin Aodong, specifically the China Merchants CSI 500 Equal Weight Index Enhanced A (009726), which reduced its holdings by 127,400 shares in the third quarter [2] - The current holding of the fund is 502,000 shares, accounting for 1% of the fund's net value, ranking as the seventh largest holding [2] - The fund has incurred a floating loss of approximately 512,000 yuan today and a total floating loss of 667,700 yuan during the five-day decline [2] Group 3: Fund Performance - The China Merchants CSI 500 Equal Weight Index Enhanced A (009726) was established on December 23, 2020, with a current scale of 480 million yuan [2] - Year-to-date return for the fund is 25.18%, ranking 1853 out of 4208 in its category; the one-year return is 22.47%, ranking 1726 out of 3972; and since inception, the return is 63.59% [2] - The fund manager, Cai Zhen, has been in position for 4 years and 110 days, with the best fund return during this period being 48.94% and the worst being 4.31% [3]